Stemline Therapeutic (STML) Stock Price, Quote, News and Overview
NASDAQ:STML - Nasdaq -
STML Quote, Performance and Key Statistics
11.83
-0.17 (-1.42%)
The current stock price of STML is 11.83 null. In the past month the price decreased by -2.75%. In the past year, price decreased by -16.51%.
About STML
Company Profile
Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.
Company Info
Stemline Therapeutic
750 LEXINGTON AVENUE ELEVENTH FLOOR
NEW YORK NY 10022
CEO: Ivan Bergstein
Phone: 646-502-2311
Stemline Therapeutic / STML FAQ
What is the stock price of Stemline Therapeutic today?
The current stock price of STML is 11.83 null. The price decreased by -1.42% in the last trading session.
What is the ticker symbol for Stemline Therapeutic stock?
The exchange symbol of Stemline Therapeutic is STML and it is listed on the Nasdaq exchange.
On which exchange is STML stock listed?
STML stock is listed on the Nasdaq exchange.
What is Stemline Therapeutic worth?
Stemline Therapeutic (STML) has a market capitalization of 621.21M null. This makes STML a Small Cap stock.
What are the support and resistance levels for Stemline Therapeutic (STML) stock?
Stemline Therapeutic (STML) has a support level at 11.82 and a resistance level at 11.91. Check the full technical report for a detailed analysis of STML support and resistance levels.
Should I buy Stemline Therapeutic (STML) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STML, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STML, evaluating the profitability, health, valuation and growth aspects
- Stemline Therapeutic (STML) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Stemline Therapeutic (STML) Sales and EPS estimates to see what analysts future expectations are.
- Stemline Therapeutic (STML) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Stemline Therapeutic (STML) Insider and Institutional Ownership to learn about the owners and their transactions.
- Stemline Therapeutic (STML) Stock Chart to make your own analysis
- Stemline Therapeutic (STML) Latest news and press-releases to stay up to date.
Does Stemline Therapeutic (STML) stock pay dividends?
STML does not pay a dividend.
What is the Price/Earnings (PE) ratio of Stemline Therapeutic (STML)?
Stemline Therapeutic (STML) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.59).
STML Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to STML. When comparing the yearly performance of all stocks, STML is one of the better performing stocks in the market, outperforming 93.31% of all stocks.
STML Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to STML. While STML has a great health rating, there are worries on its profitability.
STML Financial Highlights
Over the last trailing twelve months STML reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS increased by 47.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -150.3% | ||
| ROA | -41.44% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
STML Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to STML. The Buy consensus is the average rating of analysts ratings from 7 analysts.